Call us today: +44 (0) 20 3551 6634
Expatriates may soon expect tranexamic acid when being treated in overseas healthcare facilities for traumatic bleeding, following the results of a recent study.
The research, which was published on bmj.com, suggested that this clot stabiliser drug can safely be administered to a wide number of patients who are bleeding.
Its use does not have to be restricted to only the most severe cases, which is currently what happens in countless international healthcare centres.
Previously, investigations have shown that tranexamic acid can cause a significant reduction in death rates without increasing the likelihood of recipients incurring thrombotic adverse effects, such as the formation of a blood clot within a vein or artery.
Scientists at the London School of Hygiene & Tropical Medicine established a controlled, substantial and randomised trial to discover a prediction model that could pinpoint which patients have traumatic bleeding that could be life-threatening.
All patients were given treatment within three hours of injury and the investigators utilised their prediction model to see if the drugs and care provided to them varied alongside the baseline death risk.
When the results were revealed, it was seen that 1.5 per cent of all patients who suffered from thrombotic events and who were treated with tranexamic acid died.
However, among those who were not given tranexamic acid, the number who died reached 2.1 per cent.
Furthermore, there was also a significant reduction in the likelihood of unwanted clotting occurring among those treated with tranexamic acid, with this danger remaining the same when compared against baseline risk.
In particular, there was a significant reduction in the likelihood of a patient suffering from a heart attack.
The researchers pointed out that by only using tranexamic acid among the most at-risk patients, many of its benefits are missed out.
As a result, the international healthcare specialists concluded that the drug can be safely given to a wide range of people suffering from bleeding trauma.
Common side-effects of tranexamic acid include diarrhoea and nausea.
Expatriate Healthcare specialise in providing international health insurance. Make sure you're protected. © Expatriate Healthcare
Expatriate Group.Delmon House,36-38 Church Road,Burgess Hill,West Sussex,RH15 9AE
Registered Address.35 Ballards Lane,London,N3 1XW
Tel: +44 (0)20 3551 6634Fax: +44 (0)870 428 5141Email: firstname.lastname@example.org
Short Term Healthcare Insurance
Travel Medical Insurance One Way Travel Insurance Single Trip Travel Insurance Annual Multi-Trip Travel Insurance Non UK Resident Travel Insurance Business Travel Insurance
About Us Useful Links Leave a Review Our Awards The Press Room Satisfaction Survey Downloads Legal Notice Underwriters Hospital List
Emergency Assistance information Short-Term Healthcare Working Abroad Insurance Thailand Health Insurance Family & Friend Benefits
Register as an Intermediary Opportunities for Brokers
Expatriate Group & Expatriate Healthcare are trading styles of Strategic Insurance Services Limited who is authorised and regulated by the Financial Conduct Authority (FCA). FCA Firm reference Number is 307133. Strategic Insurance Services Limited is authorised to carry on Regulated Activities in accordance with the permissions granted by the FCA under PART IV of the Financial Services and Markets ACT 2000.